This was all over the news last night and this morning. A recent study aimed to target the removal of Beta Amyloid, which is the protein in the brain believed to be the cause of Alzheimer's disease, has shown some encouraging results. So far, it appears that the drug solanezumab can slow the progression of Alzheimer's in mid-stage patients. In an earlier trial the drug had no effect on late stage patients but in the second trial it slowed the progression by 20%. Please read these related articles.
About Me
- Tuesdays with Tom
- Chico, CA, United States
- Tom Cullen is the owner of Community Care Options, a California State approved vendor operated by a team of caring professionals with more than 30 years of experience in the field. Community Care Options is dedicated to providing continuing education to administrators of both Residential Care Facilities for the Elderly and Adult Residential Facilities and assist in keeping those facilities compliant with state regulations.
